US20130109856A1 - Novel process for the preparation of acylguanidines and acylthioureas - Google Patents

Novel process for the preparation of acylguanidines and acylthioureas Download PDF

Info

Publication number
US20130109856A1
US20130109856A1 US13/662,792 US201213662792A US2013109856A1 US 20130109856 A1 US20130109856 A1 US 20130109856A1 US 201213662792 A US201213662792 A US 201213662792A US 2013109856 A1 US2013109856 A1 US 2013109856A1
Authority
US
United States
Prior art keywords
formula
denotes
compound
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/662,792
Other languages
English (en)
Inventor
Joerg Kley
Daniel HAERLE
Guenter Linz
Sandra STEHLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Assigned to BOEHRINGER INGELHEIM INTERNATIONAL GMBH reassignment BOEHRINGER INGELHEIM INTERNATIONAL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STEHLE, Sandra, HAERLE, Daniel, KLEY, JOERG, LINZ, GUENTER
Publication of US20130109856A1 publication Critical patent/US20130109856A1/en
Priority to US14/047,043 priority Critical patent/US8791260B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/14Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/10Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/48Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C07D241/30Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C07D241/30Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
    • C07D241/32(Amino-pyrazinoyl) guanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Definitions

  • the present invention relates to a novel process for the preparation of compounds of general formula (I)
  • tert-butyl-methylisoxazolium perchlorate also referred to as “Woodward's reagent L” is known from the prior art as an intermediate for the synthesis of compounds of formula (III) (Laeckmann, D. et al. Bioorg. Med. Chem. 10 (2002) 1793-1804). Due to the known oxidizing properties of the perchlorate ion, the use of tert-butyl-methylisoxazolium perchlorate may constitute a substantial hazard, especially when applied in larger scale.
  • the problem of the present invention is to provide a process, which avoids the use of highly hazardous intermediates or reagents, for preparing compounds of formula (I).
  • Especially the problem of the present invention is to provide a process, which avoids the use of highly hazardous intermediates, for preparing compounds of formula (III) or (IV).
  • Especially the problem of the present invention is to provide a process for preparing compounds of formula (I) without the use of 2-tert-butyl-5-methyl-1,2-oxazol-2-ium perchlorate, other perchlorate salts, perchloric acid, HATU, O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) or other reagents based on 1-hydroxy-7-azabenzotriazole (HOAt) or 1-hydroxybenzotriazole (HOBT) or hydrogen sulphide.
  • exothermic decomposition energy of reagents and intermediates applied in the process should be less than 2000 J/g and the onset of exothermic decomposition (if applicable) should be above 180° C.
  • onset of exothermic decomposition if applicable
  • Differential Scanning calorimetry data Closed gold vessel
  • the present invention solves the above-mentioned problems by the method of synthesis described hereinafter.
  • the invention thus relates to a process for the preparation of compounds of general formula (I)
  • R 1 denotes a group of formula (i)
  • a further embodiment of the current invention is a process for the preparation of compounds of general formula (III)
  • the invention further relates to a process for the preparation of compounds of general formula (II),
  • the invention further relates to a compound of formula (II),
  • Preferred is a compound wherein X ⁇ denotes PF 6 ⁇ and R t denotes methyl.
  • the invention further relates to the use of a compound of formula (II) for the preparation of acylguanidines and acylthioureas, preferably for the preparation of acylguanidines.
  • the invention further relates to the use of a compound of formula (II) for the preparation of carboxylic acid 2-(2-methyl-C 1-6 -alk-2-yl)carbamoyl-1-methyl-vinyl esters, preferably for the preparation of a compound of formula (III).
  • the invention further relates to a compound of formula (III.1)
  • the compounds according to the invention may be present in the form of the tautomers as well as in the form of the free bases or the corresponding acid addition salts with pharmaceutically acceptable acids—such as for example acid addition salts with hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, or maleic acid.
  • pharmaceutically acceptable acids such as for example acid addition salts with hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, or maleic acid.
  • radicals, or moieties defined below the number of carbon atoms is often specified preceding the group, for example, —C 1-6 -alkyl means an alkyl group or radical having 1 to 6 carbon atoms.
  • the last named group is the radical attachment point, for example, “thioalkyl” means a monovalent radical of the formula HS-Alk-.
  • conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups.
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound.
  • lower-molecular groups regarded as chemically meaningful are groups consisting of 1-200 atoms. Preferably such groups have no negative effect on the pharmacological efficacy of the compounds.
  • the groups may comprise:
  • pharmaceutically acceptable prodrug means a prodrug of a compound of the invention which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible.
  • phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic,
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • aryl as used herein, either alone or in combination with another substituent, means either an aromatic monocyclic system or aromatic multicyclic systems containing carbon atoms.
  • aryl includes a phenyl or a naphthyl ring system, wherein aryl means generally an aromatic system, for example phenyl.
  • heteroaryl denotes five- or six-membered heterocyclic aromatic groups or 5-10 membered, bicyclic heteroaryl rings which may contain one, two or three heteroatoms, selected from among oxygen, sulphur and nitrogen, which contain sufficient conjugated double bonds that an aromatic system is formed.
  • the ring may be linked to the molecule through a carbon atom or if present through a nitrogen atom.
  • five- or six-membered heterocyclic aromatic groups denotes five- or six-membered heterocyclic aromatic groups or 5-10 membered, bicyclic heteroaryl rings which may contain one, two or three heteroatoms, selected from among oxygen, sulphur and nitrogen, which contain sufficient conjugated double bonds that an aromatic system is formed.
  • the ring may be linked to the molecule through a carbon atom or if present through a nitrogen atom.
  • Examples of 5-10-membered bicyclic heteroaryl rings include pyrrolizine, indole, indolizine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyrane, benzothiazole, benzoisothiazole, pyridopyrimidine, pteridine and pyrimidopyrimidine.
  • annelated species of aryl or heteroaryl as used herein, either alone or in combination with another substituent wherein the annelated species presents as a aryl-het (a), a het-aryl (b) or a het-het (c) annelation means a monovalent substituent derived by removal of one hydrogen from
  • an aromatic monocyclic system or aromatic multicyclic systems containing carbon atoms which is annelated to a five-, six- or seven-membered saturated or unsaturated (including aromatic) heterocycle containing carbon atoms and one, two, three or four ring heteroatoms selected from nitrogen, oxygen and sulfur or
  • a five-, six-, or seven-membered saturated or unsaturated (including aromatic) heterocycle containing carbon atoms and one, two, three or four ring heteroatoms selected from nitrogen, oxygen and sulfur which is annelated to a five-, six-, or seven-membered saturated or unsaturated (including aromatic) heterocycle containing carbon atoms and one, two, three or four ring heteroatoms selected from nitrogen, oxygen and sulfur.
  • Suitable examples of an annelated species of aryl or het include: quinolinyl, 1-indoyl, 3-indoyl, 5-indoyl, 6-indoyl, indolizinyl, benzimidazyl or purinyl.
  • halogen as used herein means a halogen substituent selected from fluoro, chloro, bromo or iodo.
  • C 1-6 -alkyl (including those which are part of other groups) are meant branched and unbranched alkyl groups with 1 to 6 carbon atoms, and by the term “C 1-4 -alkyl” are meant branched and unbranched alkyl groups with 1 to 4 carbon atoms.
  • Alkyl groups with 1 to 4 carbon atoms are preferred. Examples of these include: methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl or hexyl.
  • Me, Et, n-Pr, i-Pr, n-Bu, i-Bu, t-Bu, etc. may optionally also be used for the above-mentioned groups.
  • the definitions propyl, butyl, pentyl and hexyl include all the possible isomeric forms of the groups in question.
  • propyl includes n-propyl and iso-propyl
  • butyl includes iso-butyl, sec-butyl and tert-butyl etc.
  • C 1-6 -alkylene (including those which are part of other groups) are meant branched and unbranched alkylene groups with 1 to 6 carbon atoms and by the term “C 1-4 -alkylene” are meant branched and unbranched alkylene groups with 1 to 4 carbon atoms.
  • Alkylene groups with 1 to 4 carbon atoms are preferred. Examples include: methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene, pentylene, 1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene, 1,3-dimethylpropylene or hexylene.
  • propylene, butylene, pentylene and hexylene also include all the possible isomeric forms of the relevant groups with the same number of carbons.
  • propyl also includes 1-methylethylene and butylene includes 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene.
  • C 2-6 -alkenyl denotes branched and unbranched alkenyl groups with 2 to 6 carbon atoms and the term “C 2-4 -alkenyl” denotes branched and unbranched alkenyl groups with 2 to 4 carbon atoms, provided that they have at least one double bond.
  • alkenyl groups with 2 to 4 carbon atoms examples include: ethenyl or vinyl, propenyl, butenyl, pentenyl, or hexenyl. Unless otherwise stated, the definitions propenyl, butenyl, pentenyl and hexenyl include all possible isomeric forms of the groups in question. Thus, for example, propenyl includes 1-propenyl and 2-propenyl, butenyl includes 1-, 2- and 3-butenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl etc.
  • C 2-6 -alkenylene (including those which are part of other groups) are meant branched and unbranched alkenylene groups with 2 to 6 carbon atoms and by the term “C 2-4 -alkenylene” are meant branched and unbranched alkylene groups with 2 to 4 carbon atoms. Alkenylene groups with 2 to 4 carbon atoms are preferred.
  • Examples include: ethenylene, propenylene, 1-methylethenylene, butenylene, 1-methylpropenylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene, pentenylene, 1,1-dimethylpropenylene, 2,2-dimethylpropenylene, 1,2-dimethylpropenylene, 1,3-dimethylpropenylene or hexenylene.
  • the definitions propenylene, butenylene, pentenylene and hexenylene include all the possible isomeric forms of the respective groups with the same number of carbons.
  • propenyl also includes 1-methylethenylene and butenylene includes 1-methylpropenylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene.
  • C 2-6 -alkynyl (including those which are part of other groups) are meant branched and unbranched alkynyl groups with 2 to 6 carbon atoms and by the term “C 2-4 -alkynyl” are meant branched and unbranched alkynyl groups with 2 to 4 carbon atoms, provided that they have at least one triple bond.
  • Alkynyl groups with 2 to 4 carbon atoms are preferred. Examples include: ethynyl, propynyl, butynyl, pentynyl, or hexynyl.
  • propynyl, butynyl, pentynyl and hexynyl include all the possible isomeric forms of the respective groups.
  • propynyl includes 1-propynyl and 2-propynyl
  • butynyl includes 1-, 2- and 3-butynyl, 1-methyl-1-propynyl, 1-methyl-2-propynyl etc.
  • C 2-6 -alkynylene (including those which are part of other groups) are meant branched and unbranched alkynylene groups with 2 to 6 carbon atoms and by the term “C 2-4 -alkynylene” are meant branched and unbranched alkylene groups with 2 to 4 carbon atoms. Alkynylene groups with 2 to 4 carbon atoms are preferred.
  • Examples include: ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene, pentynylene, 1,1-dimethylpropynylene, 2,2-dimethylpropynylene, 1,2-dimethylpropynylene, 1,3-dimethylpropynylene or hexynylene.
  • the definitions propynylene, butynylene, pentynylene and hexynylene include all the possible isomeric forms of the respective groups with the same number of carbons.
  • propynyl also includes 1-methylethynylene and butynylene includes 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene.
  • C 1-6 -alkoxy (including those which are part of other groups) are meant branched and unbranched alkoxy groups with 1 to 6 carbon atoms and by the term “C 1-4 -alkoxy” are meant branched and unbranched alkoxy groups with 1 to 4 carbon atoms. Alkoxy groups with 1 to 4 carbon atoms are preferred. Examples include: methoxy, ethoxy, propoxy, butoxy or pentoxy.
  • OMe, OEt, OPr, etc. may optionally be used for the above-mentioned groups.
  • the definitions propoxy, butoxy and pentoxy include all the possible isomeric forms of the respective groups.
  • propoxy includes n-propoxy and iso-propoxy
  • butoxy includes iso-butoxy, sec-butoxy and tert-butoxy etc.
  • C 3-8 -cycloalkyl (including those which are part of other groups) as used herein means cyclic alkyl groups with 3 to 8 carbon atoms, preferred are cyclic alkyl groups with 5 to 6 carbon atoms. Examples include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
  • C 3-6 -cycloalkenyl is a cyclic alkyl group meant with 5 or 6 carbon atoms which contain one or two double bonds. Examples include: cyclopentenyl, cyclopentadienyl, cyclohexenyl or cyclohexadienyl.
  • C 1-6 -haloalkyl (including those which are part of other groups) are meant branched and unbranched alkyl groups with 1 to 6 carbon atoms wherein one or more hydrogen atoms are replaced by a halogen atom selected from among fluorine, chlorine or bromine, preferably fluorine and chlorine, particularly preferably fluorine.
  • C 1-4 -haloalkyl are meant correspondingly branched and unbranched alkyl groups with 1 to 4 carbon atoms, wherein one or more hydrogen atoms are replaced analogously to what was stated above.
  • C 1-4 -haloalkyl is preferred. Examples include: CH 2 F, CHF 2 , CF 3 ,
  • the substituent R 1 denotes a group of formula (i),
  • the substituent R 2 denotes hydrogen or a group selected from among C 1-6 -alkyl, C 6-10 -aryl-C 1-6 -alkyl-, heterocyclyl, heterocyclyl-CH 2 —, —, preferably benzyl,
  • R 2 denotes a group of formula (ii)
  • the substituent R 4 may denote a group selected from among alkylthio, 1-pyrazolyl, 1-imidazolyl and 1,2,4-triazol-1-yl, each optionally substituted by one or two methyl groups, preferably 1-pyrazolyl.
  • the substituent R t denotes a group selected from among C 1-4 -alkyl, preferably methyl or ethyl.
  • X ⁇ denotes a group selected from among PF 6 ⁇ , BF 4 ⁇ , SbF 6 ⁇ , phenylsulphonate, p-toluenesulphonate, HSO 4 ⁇ , (SO 4 2 ⁇ )/2, FSO 3 ⁇ and F 3 CSO 3 ⁇ ; preferably PF 6 ⁇ and F 3 CSO 3 ⁇ .
  • Process step (A) is preferably carried out neat or in a solvent selected from among water, methanol, ethanol, tetrahydrofuran (THF), diethylether, tert-butyl-methylether, dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), N-ethyl-2-pyrrolidone (NEP) and dimethylsulphoxide (DMSO), or mixtures thereof, preferably in a mixture containing water and tetrahydrofuran (THF) and/or diethylether.
  • a solvent selected from among water, methanol, ethanol, tetrahydrofuran (THF), diethylether, tert-butyl-methylether, dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), N-ethyl-2-pyrrolidone (NEP) and dimethylsulphoxide (DMSO), or mixtures thereof, preferably in a mixture containing water and
  • Process step (A) is carried out in a temperature range of from ⁇ 20° C. to 40° C., preferably from 0° C. to 25° C.
  • Process step (B) is preferably carried out in the presence of a base selected from among triethylamine, di-isopropyl-ethylamine and N-methylmorpholine, preferably triethylamine.
  • Process step (B) is preferably carried out in a solvent selected from among DMF, NMP, NEP and DMSO, preferably in DMF.
  • Process step (B) is preferably carried out at an initial temperature ranging from 20° C. to 60° C., particularly preferably from 20° C. to 50° C.
  • the temperature is allowed to lower during the process, most preferably to ambient temperature.
  • the skilled person will appreciate that depending on R 1 , the addition of water at a later timepoint during the process may promote precipitation of the compound of formula (III) formed during the process.
  • the final temperature when separating the product is preferably ⁇ 20° C. to 25° C., most preferably 0° C. to 20° C.
  • Process step (C) is preferably carried out with the addition of a base selected from among triethylamine, di-isopropyl-ethylamine and N-methylmorpholine, preferably triethylamine.
  • Process step (C) is preferably carried out neat or applying a solvent selected from among DMF, NMP, NEP and DMSO, preferably DMF.
  • Stage 1 of process step (C) is preferably carried out in a temperature range of from 0° C. to 30° C., preferably from 0° C. to 20° C., particularly preferable at a temperature from 0° C. to 5° C.
  • the skilled person will appreciate that depending on R 1 , the addition of water at a later timepoint during the process may promote precipitation of the compound of formula (III) formed during the process.
  • the final temperature when separating the product is preferably 0° C. to 25° C., most preferably 0° C. to 20° C.
  • Process step (D) is preferably carried out applying a base selected from among sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate, potassium tert-butylate, sodium methanolate and sodium ethanolate, preferably sodium hydroxide and potassium tert-butylate.
  • a base selected from among sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate, potassium tert-butylate, sodium methanolate and sodium ethanolate, preferably sodium hydroxide and potassium tert-butylate.
  • Process step (D) is preferably carried out applying a solvent selected from among tert-butylmethyl ether (TBME), tetrahydrofuran (THF), dichlormethane (DCM), acetonitrile, diethylether, dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), N-ethyl-2-pyrrolidone (NEP) and dimethylsulphoxide (DMSO), or mixtures thereof, preferably TBME, THF and DCM, or a mixture thereof, particularly preferable TBME and THF or a mixture thereof.
  • a solvent selected from among tert-butylmethyl ether (TBME), tetrahydrofuran (THF), dichlormethane (DCM), acetonitrile, diethylether, dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), N-ethyl-2-pyrrolidone (NEP) and dimethylsulphoxid
  • Process step (D) is preferably carried out in a temperature range of from 15° C. to the boiling point of the solvent applied. With the proviso that R 4 denotes alkylthio, process step (D) is most preferably carried out at a temperature from 15 to 25° C.
  • Process step (E) is preferably carried out in the presence of a base selected from among sodium hydroxide, sodium carbonate, potassium hydroxide, potassium carbonate, sodium methanolate, sodium ethanolate and potassium tert-butanolate. Also preferred is the process step (E) carried out in the presence of an alcoholate generated by addition of sodium or sodium hydride to a solvent selected from methanol, ethanol, 2-propanol and tert-butanol.
  • a base selected from among sodium hydroxide, sodium carbonate, potassium hydroxide, potassium carbonate, sodium methanolate, sodium ethanolate and potassium tert-butanolate.
  • an alcoholate generated by addition of sodium or sodium hydride to a solvent selected from methanol, ethanol, 2-propanol and tert-butanol.
  • the process step is carried out in the presence of a base selected from among sodium hydroxide, potassium hydroxide, sodium ethanolate, sodium 2-propanolate, sodium tert-butanolate and potassium tert-butanolate which in the case of sodium alcoholates may be generated by addition of metallic sodium or sodium hydride to the respective alcohol.
  • a base selected from among sodium hydroxide, potassium hydroxide, sodium ethanolate, sodium 2-propanolate, sodium tert-butanolate and potassium tert-butanolate which in the case of sodium alcoholates may be generated by addition of metallic sodium or sodium hydride to the respective alcohol.
  • formula (VIII) is preferably used as a free base or as an acid addition salt, preferably as an acid addition salt selected from among hydrochloric acid, hydrobromic acid, sulphuric acid, methylsulphonic acid and p-tolylsulphonic acid.
  • Process step (E) is preferably carried out in a solvent selected from among tetrahydrofuran (THF), dioxane, methanol, ethanol, 2-propanol and tert-butanol or a mixture thereof, most preferably in ethanol and 2-propanol.
  • a solvent selected from among tetrahydrofuran (THF), dioxane, methanol, ethanol, 2-propanol and tert-butanol or a mixture thereof, most preferably in ethanol and 2-propanol.
  • Process step (E) is preferably carried out in a temperature range of from 40° C. to 90° C., preferably from 50° C. to 85° C.
  • Process step (F) is preferably carried out in the presence of a base selected from among triethylamine di-isopropyl-ethylamine and N-methylmorpholine, preferably triethylamine.
  • Process step (F) is preferably carried out in a solvent selected from among methanol, ethanol, 2-propanol, acetonitrile, DCM, tetrahydrofuran (THF), diethylether, dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), N-ethyl-2-pyrrolidone (NEP) and dimethylsulphoxide (DMSO), or mixtures thereof, preferably selected from among methanol, ethanol, DMF and THF or mixtures thereof, most preferably in ethanol and DMF.
  • a solvent selected from among methanol, ethanol, 2-propanol, acetonitrile, DCM, tetrahydrofuran (THF), diethylether, dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), N-ethyl-2-pyrrolidone (NEP) and dimethylsulphoxide (DMSO), or mixtures thereof, preferably selected from among
  • Process step (F) is preferably carried out in a temperature range of from 50° C. to 90° C., preferably from 65° C. to 80° C.
  • the precipitate is filtered off with suction, taken up in THF/water (1:4; 75 ml), filtered again with suction and washed with water.
  • the product is dried in vacuo at 60° C. (C 14 H 20 ClN 5 O 3 ).
  • HPLC Analytics HPLC method 1 Column: Sunfire C18, 4.6 ⁇ 30 mm, 2.5 ⁇ m Supplier: Waters Gradient: % Sol % Sol Flow Temp time [min] [H2O, 0.1% TFA] [Methanol] [ml/min] [° C.] 0.0 95 5 4 60 0.05 95 5 3 60 2.05 0 100 3 60 2.10 0 100 4.5 60 2.40 0 100 4.5 60 HPLC method 2
  • TLC silica glass plates from Merck are used (TLC Silica Gel 60F 254 ; 1.05729.0001).
  • r.t. ambient temperature e.g. 18 to 25° C., preferably 20° C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US13/662,792 2011-11-02 2012-10-29 Novel process for the preparation of acylguanidines and acylthioureas Abandoned US20130109856A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/047,043 US8791260B2 (en) 2011-11-02 2013-10-07 Process for the preparation of acylguanidines and acylthioureas

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11187566.2 2011-11-02
EP11187566 2011-11-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/047,043 Division US8791260B2 (en) 2011-11-02 2013-10-07 Process for the preparation of acylguanidines and acylthioureas

Publications (1)

Publication Number Publication Date
US20130109856A1 true US20130109856A1 (en) 2013-05-02

Family

ID=47080525

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/662,792 Abandoned US20130109856A1 (en) 2011-11-02 2012-10-29 Novel process for the preparation of acylguanidines and acylthioureas
US14/047,043 Active US8791260B2 (en) 2011-11-02 2013-10-07 Process for the preparation of acylguanidines and acylthioureas

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/047,043 Active US8791260B2 (en) 2011-11-02 2013-10-07 Process for the preparation of acylguanidines and acylthioureas

Country Status (14)

Country Link
US (2) US20130109856A1 (ru)
EP (1) EP2773624A1 (ru)
JP (1) JP2015501324A (ru)
KR (1) KR20140095057A (ru)
CN (1) CN104024231A (ru)
AU (1) AU2012331275A1 (ru)
BR (1) BR112014010462A2 (ru)
CA (1) CA2854221A1 (ru)
CL (1) CL2014001046A1 (ru)
EA (1) EA201400522A1 (ru)
IL (1) IL232036A0 (ru)
MX (1) MX2014005165A (ru)
PH (1) PH12014500969A1 (ru)
WO (1) WO2013064451A1 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159028A3 (en) * 2021-01-25 2022-09-29 Phamri Norden Ab Method of treating a skin disorder by administering an amiloride derivative
WO2023052449A1 (en) 2021-09-28 2023-04-06 Psomri Holding Ab New salt forms of amiloride and its derivatives for pharmaceutical use

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013064450A1 (en) 2011-11-02 2013-05-10 Boehringer Ingelheim International Gmbh Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7421416B2 (en) * 2003-04-04 2008-09-02 Nhn Corporation Method of managing web sites registered in search engine and a system thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6812003A (ru) * 1967-09-07 1969-03-11
US3503972A (en) * 1968-11-04 1970-03-31 Merck & Co Inc Alkyl n-amidino (or guanidino)-pyrazinimidates
US3953476A (en) 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
EP0798311A1 (en) * 1996-03-25 1997-10-01 National Starch and Chemical Investment Holding Corporation Starch degradation using metal-based coordination complexes
JPH1029375A (ja) * 1996-07-17 1998-02-03 Fuji Photo Film Co Ltd 感熱記録材料及び熱記録方法
CN101687851B (zh) * 2007-05-07 2013-02-27 诺瓦提斯公司 有机化合物
CL2008003651A1 (es) * 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
AU2009248179A1 (en) 2008-05-13 2009-11-19 Novartis Ag 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
HUE032851T2 (en) 2011-06-27 2017-11-28 Parion Sciences Inc A chemically and metabolically stable dipeptide having strong sodium channel blocking activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7421416B2 (en) * 2003-04-04 2008-09-02 Nhn Corporation Method of managing web sites registered in search engine and a system thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DeLaCal et al., caplus an 1990:98124 *
ListofPharmaceuticallyAcceptableSalts, 2005, Electronic Supplementary Material for CrystEngComm *
Maran et al., caplus an 1973:12060 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159028A3 (en) * 2021-01-25 2022-09-29 Phamri Norden Ab Method of treating a skin disorder by administering an amiloride derivative
WO2023052449A1 (en) 2021-09-28 2023-04-06 Psomri Holding Ab New salt forms of amiloride and its derivatives for pharmaceutical use

Also Published As

Publication number Publication date
BR112014010462A2 (pt) 2017-04-18
MX2014005165A (es) 2014-05-28
PH12014500969A1 (en) 2017-08-23
KR20140095057A (ko) 2014-07-31
EP2773624A1 (en) 2014-09-10
JP2015501324A (ja) 2015-01-15
CA2854221A1 (en) 2013-05-10
EA201400522A1 (ru) 2014-10-30
CL2014001046A1 (es) 2014-11-14
IL232036A0 (en) 2014-05-28
US8791260B2 (en) 2014-07-29
AU2012331275A1 (en) 2014-04-03
US20140039189A1 (en) 2014-02-06
WO2013064451A1 (en) 2013-05-10
CN104024231A (zh) 2014-09-03

Similar Documents

Publication Publication Date Title
EP1812439B1 (en) Kinase inhibitors
EP2133349B1 (en) Kinase inhibitors
US20080153869A1 (en) Kinase Inhibitors
US20070173527A1 (en) Histone deacetylase inhibitors
US9937155B2 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
CA2681809C (en) Imidazolidinone derivatives
CN105683167B (zh) 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂
AU2017378324A1 (en) Bycyclic heteroaryl derivatives as CFTR potentiators
JP2009508873A (ja) ジペプチジルペプチダーゼ阻害剤
JP2009532375A (ja) キナーゼ阻害剤
US20100160633A1 (en) Kinase inhibitors
CN106488918B (zh) 三唑并嘧啶酮或三唑并吡啶酮衍生物及其用途
JP2010507581A (ja) PKC−θ阻害薬としてのプリン類
US8791260B2 (en) Process for the preparation of acylguanidines and acylthioureas
RS55201B1 (sr) Antimalarijski agensi
CA2912338C (en) Pyridone derivatives for the treatment of viral infections and further diseases
EP4274572B1 (en) Novel inhibitors of autotaxin
US7550598B2 (en) Kinase inhibitors
SG175609A1 (en) Kinase inhibitors
WO2025242233A1 (zh) 一种酰胺吲嗪类化合物及其制备方法和应用
CN121517430A (zh) Cdk2降解剂及其制备方法和应用
HK40096093B (en) Novel inhibitors of autotaxin
HK40096093A (en) Novel inhibitors of autotaxin
NZ709769A (en) 2-aminopyrimidine derivatives for the treatment of viral infections
HK1219946B (zh) 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KLEY, JOERG;HAERLE, DANIEL;LINZ, GUENTER;AND OTHERS;SIGNING DATES FROM 20121113 TO 20121121;REEL/FRAME:029392/0314

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION